Page 25 - SDIR5 Abstract book 21 12 2021.
P. 25

CANCER AND METABOLISM


                       Hsa-miR-222 identifies high-risk PTC patients with classical variant architecture

                                                                                                   2
                                                                                  1
                Stefana Stojanović , Sonja Šelemetjev , Ilona Đorić , Jelena Janković Miljuš , Vladan Živaljević , Svetislav
                                 1
                                                             1
                                                  1
                                                        3
                                                                         1
                                                   Tatić , Tijana Išić Denčić
                        1 Institute for the Application of Nuclear Energy — INEP, University of Belgrade, Belgrade, Serbia
                2 Center for Endocrine Surgery, Institute of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of
                                                     Serbia, Belgrade, Serbia
                              3 Institute of Pathology, Medical Faculty, University of Belgrade, Belgrade, Serbia

               Background: Finding novel tumor markers useful to recognize high-risk thyroid carcinoma patients is of
               great  importance.  We  evaluated  hsa-microRNA-222  (miR-222)  for  differential  diagnosis  of  thyroid
               neoplastic  lesions  and  assessed  its  prognostic  usefulness.  Material  and  Methods: MiR-222  levels  were
               determined in 77 cases of papillary thyroid carcinomas (PTC) of diverse histological variants, 12 cases of
               follicular thyroid adenoma (FTA), and 99 matched nonmalignant thyroid epithelial tissues (NMT) using RT-
               qPCR. The results were evaluated in comparison with clinicopathological features of PTC. Results: Relative
               miR-222 expression is higher in PTC than in FTA and NMT (p<0.05). Compared to the levels in paired NMT,
               miR-222 is up-regulated in PTC, while being down-regulated in FTA (median 2.22 [0.71–8.81] vs. 0.40 [0.09–
               2.07], p<0.05). Althought increased expression of miR-222 could be used as sensitive (76.6%) and specific
               (75.0%) marker for discriminating PTC from FTA (cut off=0.66, AUC=0.747, p<0.01), miR-222 expression
               depends on PTC subtype. Only PTCs with areas of classical variant architecture tend to have high values of
               miR-222 relative expression, while folicular variant of PTC and selected rare PTC variants (Warthin-like, tall
               cell,  solid,  clear  cell,  oxyphilic)  tend  to  have  lower  values  (p<0.05).  Higher  miR-222  expression  in  PTC
               associate with the presence of metastasis in the regional lymph nodes, the presence of extrathyroidal
               invasion, degree of tumor infiltration through the gland, higher pT and pTNM stage (p<0.05). Conclusions:
               MiR-222  is  a  useful  marker  for  PTC  detection,  particularly  its  classical  variant,  and  can  help  in  risk
               stratification of these patients.
               Keywords: Diagnosis, Micro RNA, Papillary Thyroid Carcinoma, Prognosis, Tumor Marker

































                                                             12
   20   21   22   23   24   25   26   27   28   29   30